Core--Tissue procurement

描述：（申请人描述）该核心旨在成为孢子的整体资源，并为当前和未来的项目和试点研究提供有价值的生物材料来源。实验室核心将负责收集、储存和分配卵巢组织和肿瘤。新鲜/冷冻样品将在FCCC和其他参与站点收集并转发到我们的核心实验室。该实验室核心还将负责收集档案卵巢肿瘤标本并提取DNA，以分发给参与项目和试点研究。据估计，在我们的提案过程中，每年将有超过400例新的卵巢癌病例通过OCCN被发现（见核心1）。据非常保守的估计，这些病例中约有30%将作为新鲜/冷冻标本积累。所有病例均可获得石蜡包埋肿瘤。肿瘤样本将用于项目1、2、3和5。此外，我们将收集参与我们的化学预防试验（见项目4）的被认为患卵巢癌风险增加的妇女（如BRCA1、BRCA1突变等位基因携带者或有癌症家族史的妇女）为预防而切除的卵巢。这些组织将被处理和分发，用于病理和免疫组织化学评估，以确定芬维甲酸和其他化学预防药物对我们之前在危险卵巢中观察到的易癌表型的影响。通过将这些服务集中到一个核心，我们将能够更好地管理和协调大量高价值肿瘤、癌症易发和正常标本的收集、储存和分发。

DESCRIPTION: (Applicant's Description) This core is intended to be a resource for the SPORE as a whole and a valuable source of biological materials for the present and future projects and pilot studies. The laboratory core will be responsible for the collection, storage, and distribution of ovarian tissues and tumors. Fresh/frozen samples will be collected at FCCC and other participating sites and forwarded to our core laboratory. This laboratory core will also be responsible for the collection of archival ovarian tumor specimens and the extraction of DNA to be distributed to the participating projects and pilot studies. It is estimated that more than 400 new ovarian cancers cases will be identified each year through the OCCN (see Core 1) during the course of our proposal. It is very conservatively estimated that approximately 30 percent of these cases will be accrued as fresh/frozen specimens. Paraffin embedded tumors will be available from all cases. Tumor samples will be used by Projects 1, 2, 3 and 5. In addition, we will collect ovaries removed for prophylaxis from women considered to be at increased risk of developing ovarian cancer (e.g., BRCA1, BRCA1 mutant allele carriers, or suggestive family history of cancer) who participate in our chemoprevention trial (see Project 4). These tissues will be processed and distributed for pathology and immunohistochemical evaluation to determine the effect of fenretinide and other chemopreventive agents on the cancer-prone phenotype that we have previously observed in at risk ovaries. By centralizing these services into a core, we will be better able to manage and coordinate the collection, storage, and distribution of a large number of highly valuable tumor, cancer-prone and normal specimens.